Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880642 · ClinicalTrials.gov registry record · Phase 3
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
A Phase 3 study, sponsored by Vicore Pharma AB.
- Completed
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
NCT04880642: Completed Phase 3 study, sponsored by Vicore Pharma AB.
NCT04880642 is a Phase 3 study that has completed, run by Vicore Pharma AB. The registered enrollment target is 272 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04880642, a Phase 3 study, has completed, sponsored by Vicore Pharma AB.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
Study Summary
This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm, multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add-on to standard of care (SoC) in adult subjects with COVID-19. The trial planned to enroll a total of maximum 300 randomized subjects, 150 per arm (oral C21 100 mg twice a day (BID) or placebo for 14 days) according to the 1:1 randomization.
Primary Outcome
Proportion of subjects in the mITT (all randomised, including 5 subjects not treated) with death up to Day 60 follow-up
Interventions
- DRUG Placebo
- DRUG C21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 3 |
What the finished NCT04880642 record still lists
NCT04880642 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04880642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04880642 about?
NCT04880642 is a clinical study titled "A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects". This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm, multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add-on to standard of care (SoC) in adult subjects with COVID-19. The trial planned to enroll a total of maximum 300 randomized subject...
What is the current status of trial NCT04880642?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2021-09-16. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT04880642?
The interventions under investigation include: Placebo (DRUG), C21 (DRUG).
Who is sponsoring clinical trial NCT04880642?
This trial is sponsored by Vicore Pharma AB, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04880642's enrollment target sits among peer trials
272 1214th of 2000 higher than 785 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI